Document Detail


Gold for ubiquitin in Vancouver: First Conference on Proteomics of Protein Degradation and Ubiquitin Pathways held June 6-8, 2010 in Vancouver, University of British Columbia, organized By Lan Huang, Thibault Mayor, and Peipei Ping.
MedLine Citation:
PMID:  20834021     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The rise of proteomics has had tremendous influence on analysis and understanding of the role of post-translational modifications in biological processes. The covalent attachment of small proteins like ubiquitin, SUMO,(1) or other ubiquitin-like proteins (Ubls) is one class of post-translational modifications where proteomics has had notable impact. Various proteomics approaches, but in particular mass spectrometry-based analyses, have influenced the field and enabled significant advances over the past few years. The first meeting dedicated to proteomics of protein degradation and ubiquitin pathways showcased these advances and allowed a glimpse at future contributions of proteomics to this field. With its many attractive drug targets, the ubiquitin and proteasome system, as well as other proteolysis pathways, could offer new therapies for various human diseases including cancer and neurodegenerative disorders. The covalent linkage of ubiquitin to other proteins is catalyzed by the E1-E2-E3 cascade of enzymatic reactions whereby the many different E3 ubiquitin ligases provide substrate specificity to the process of protein ubiquitylation (1). Ubiquitylation is best known for targeting proteins for degradation by the proteasome, but other functions for ubiquitylation independent of proteolysis are also known. Likewise, modifications with SUMO or other Ubls generally do not regulate protein degradation but instead control subcellular localization, protein interactions, or change protein conformation and activity (2). The questions addressed by proteomics approaches to ubiquitylation and Ubl modifications are plentiful. They range from very specific, e.g. determination of the modified residue in a substrate protein, to complex, such as protein dynamics in proteome-wide ubiquitin (or Ubl) modification profiles (3). In either case, the rapid technological advancements (particularly in mass spectrometry instrumentation as well as quantitation and separation technologies) have allowed impressive progress, which was evident in the First Conference on Proteomics of Protein Degradation and Ubiquitin Pathways in Vancouver (http://ppdup.org/) (Fig. 1).
Authors:
Peter Kaiser; Thibault Mayor
Publication Detail:
Type:  Congresses; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2010-09-10
Journal Detail:
Title:  Molecular & cellular proteomics : MCP     Volume:  10     ISSN:  1535-9484     ISO Abbreviation:  Mol. Cell Proteomics     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-05-05     Completed Date:  2011-09-06     Revised Date:  2012-05-01    
Medline Journal Info:
Nlm Unique ID:  101125647     Medline TA:  Mol Cell Proteomics     Country:  United States    
Other Details:
Languages:  eng     Pagination:  R110.003863     Citation Subset:  IM    
Affiliation:
Department of Biological Chemistry, School of Medicine, University of California, Irvine, California 92697-1700, USA. pkaiser@uci.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Humans
Metabolic Networks and Pathways*
Proteasome Endopeptidase Complex / metabolism
Protein Transport
Proteome / metabolism*
Proteomics*
Ubiquitin / metabolism*
Ubiquitin-Protein Ligases / chemistry,  metabolism
Ubiquitinated Proteins / chemistry,  metabolism*
Ubiquitination
Grant Support
ID/Acronym/Agency:
GM-066164-06A1S1/GM/NIGMS NIH HHS; GM-066164-07/GM/NIGMS NIH HHS; R01 GM066164-09/GM/NIGMS NIH HHS
Chemical
Reg. No./Substance:
0/Proteome; 0/Ubiquitin; 0/Ubiquitinated Proteins; EC 3.4.25.1/Proteasome Endopeptidase Complex; EC 6.3.2.19/Ubiquitin-Protein Ligases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Who is Susan P Baker and why did she win the Calderone Prize?
Next Document:  Payment regulations for advanced practice nurses: implications for primary care.